H-1337 Ophthalmic Solution Phase 1/2

Status Completed

Clinical Trial Summary

The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with elevated intraocular pressure (IOP).

Clinical Trial Description

Study ALY337-201 will be a double-masked, randomized, placebo-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of H-1337 ophthalmic solution in subjects with ocular hypertension (OHT) or open angle glaucoma. During screening, subjects who meet the preliminary inclusion/exclusion criteria will discontinue use of their ocular hypotensive therapy during the washout period. The washout duration will be dependent on the subject's pre-study ocular hypotensive therapy. Starting on Day 0, those who continue to meet the inclusions/exclusion criteria and the diurnal IOP criteria will be randomized into one of the treatments arms and dosing will be initiated, continuing for 28 days. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03452033
Study type	Interventional
Source	Allysta Pharmaceutical
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	March 15, 2018
Completion date	August 15, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05044793` - A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
Recruiting	`NCT06201455` - Evaluation of Phacogoniotomy in Medically-controlled POAG	N/A
Recruiting	`NCT03369886` - The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI	N/A
Active, not recruiting	`NCT04624698` - iStent Inject New Enrollment Post-Approval Study	N/A
Recruiting	`NCT02679482` - Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma	N/A
Completed	`NCT02338362` - Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma	Phase 4
Active, not recruiting	`NCT01430923` - Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost	N/A
Completed	`NCT01489670` - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension	N/A
Completed	`NCT00753168` - Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma	Phase 1/Phase 2
Completed	`NCT00693485` - Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy	Phase 2
Completed	`NCT00051194` - A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension	Phase 2
Recruiting	`NCT04920227` - Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma	N/A
Active, not recruiting	`NCT03868124` - Clinical Study Comparing Two Models of a Travoprost Intraocular Implant	Phase 3
Completed	`NCT03267862` - Scleral Response to Intraocular Pressure (IOP)	N/A
Recruiting	`NCT06066645` - Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone	Phase 3
Recruiting	`NCT04912362` - The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma	N/A
Completed	`NCT04949802` - Glaucoma Surgery Using the ViaLase Laser System	N/A
Recruiting	`NCT04038034` - Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma	N/A
Completed	`NCT04632329` - Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma	N/A
Completed	`NCT01215786` - Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma	Phase 1